Clinical trials: Acute Coronary Syndrome (ACS)
Acute Coronary Syndrome, Depressive Symptoms
Comparison of Depression Identification After Acute Coronary Syndrome: Quality of Life and Cost Outcomes
The purpose of this study is to examine, in a randomized controlled trial, the benefits and costs of the American Heart Association's (AHA) advisory for depression screen and treatment of post-acute coronary syndrome patients.
- Trial name
- CODIACSQoL (NCT01993017)
- Testing
- Cognitive Behavioral Therapy (CBT), Antidepressant Medication, Standard Care
- Where
- 4 sites in United States
- Volunteers
- 1,501 people
- Sponsor
- Columbia University
Acute Coronary Syndrome (ACS)
Safety Study of Apixaban in Recent Acute Coronary Syndrome
The purpose of this clinical research study is to determine whether apixaban will be safe in people who have recently had unstable angina or a heart attack.
- Trial name
- NCT00313300
- Testing
- Apixaban
- Where
- 151 sites in United States, Austria and 12 more
- Volunteers
- 1,741 people
- Sponsor
- Bristol-Myers Squibb
Acute Coronary Syndrome
Treatment With Adenosine Diphosphate (ADP) Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome
The TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study is a prospective, observational longitudinal study to evaluate the real…
- Trial name
- TRANSLATE-ACS (NCT01088503)
- Testing
- ADP receptor inhibitors
- Where
- 186 sites in United States, Puerto Rico
- Volunteers
- 12,227 people
- Sponsor
- Eli Lilly and Company
Acute Coronary Syndrome
Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Patients With Acute Coronary Syndromes (The ATLAS ACS TIMI 46 Trial)
The purpose of this study is to evaluate the safety of rivaroxaban in patients with recent acute coronary syndrome (ACS) and to assess the ability of rivaroxaban to reduce the occurrence of death, myocardial infarction (heart…
- Trial name
- NCT00402597
- Testing
- Rivaroxaban
- Volunteers
- 3,490 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Acute Coronary Syndrome
Safety and Efficacy Iodofiltic Acid I 123 in the Treatment of Acute Coronary Syndrome
This is an open-label phase 2 study recruiting low, moderate, and high likelihood ACS patients from approximately 60 centers. Patients will be imaged with iodofiltic acid I 123 for the detection of myocardial ischemia.
- Trial name
- Zeus-ACS (NCT00514501)
- Testing
- Iodofiltic acid I 123
- Where
- 38 sites in United States, Canada
- Volunteers
- 510 people
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
Acute Coronary Syndrome, Myocardial Infarction
An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome
The purpose of this study is to determine whether rivaroxaban in addition to standard care reduces the risk of the composite of cardiovascular death, myocardial infarction, or stroke in patients with a recent acute coronary…
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Myocardial Ischemia, Unstable Angina
- Trial name
- NCT00809965
- Testing
- Rivaroxaban 2.5 mg, Rivaroxaban 5 mg, Standard of care
- Where
- 556 sites in United States, Argentina and 41 more
- Volunteers
- 15,526 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Myocardial Infarction, Cardiovascular Death
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
This study is being carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke).
- Conditions
- Myocardial Infarction, Cardiovascular Death, Atherothrombosis, Stroke
- Trial name
- PEGASUS (NCT01225562)
- Testing
- Ticagrelor 90 mg, Ticagrelor 60 mg
- Where
- 826 sites in United States, Argentina and 29 more
- Volunteers
- 21,379 people
- Sponsor
- AstraZeneca
Acute Coronary Syndrome
Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)
The purpose of this study is to compare the safety of two different dose regimens of unfractionated heparin (UFH) during a percutaneous coronary intervention (PCI) procedure in patients with UA (unstable angina)/NSTEMI (non ST…
- Trial name
- FUTURA/OASIS 8 (NCT00790907)
- Testing
- fondaparinux background and standard dose UFH, Fondaparinux background and low dose heparin, Open label fondaparinux
- Where
- 203 sites in United States, Argentina and 16 more
- Volunteers
- 3,235 people
- Sponsor
- GlaxoSmithKline
Depression
Treatment of Depression in Acute Coronary Syndrome (ACS) Patients
Emotional states of depression in association with ischemic heart diseases, such as myocardial infarction or unstable angina, are risk factors for subsequent cardiac events and mortality.
- Trial name
- TREATED-ACS (NCT00998400)
- Testing
- CBT in combination with WBT and life style modification
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- University of Bologna
Acute Coronary Syndrome (ACS), High On-treatment Platelet Reactivity (HTPR)
The Effect of IV Cangrelor and Oral Ticagrelor Study
Major heart attacks are caused by a number of factors, the two major of which are furring up of a coronary artery with atheroma and then sudden clot formation on this area leading to a blockage and interruption of blood flow.
- Conditions
- Acute Coronary Syndrome (ACS), High On-treatment Platelet Reactivity (HTPR), Microvascular Obstruction (MVO), ST-segment Elevation Myocardial Infarction (STEMI)
- Trial name
- NCT02733341
- Testing
- Cangrelor, Ticagrelor
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
Acute Coronary Syndrome, Myocardial Infarction
Zyban as an Effective Smoking Cessation Aid for Patients Following an Acute Coronary Syndrome: The ZESCA Trial
Patients who continue to smoke after a heart attack have a 35% increased risk of a recurrent event or death compared with those who quit. Many patients attempt to stop smoking after a heart attack, but relapse rates approach 66%.
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Smoking
- Trial name
- ZESCA (NCT00689611)
- Testing
- Bupropion HCl ER
- Where
- 38 sites in United States, Bangladesh and 5 more
- Volunteers
- 392 people
- Sponsor
- Mark Eisenberg
Acute Coronary Syndromes (ACS)
Association Between SYNTAX Score and Leukoglycemic Index In Patients Wiht Acute Coronary Syndrome
This study looks at people who come to the hospital with acute coronary syndrome, a serious heart condition. When these patients first arrive, doctors take routine blood tests.
- Trial name
- NCT07276256
- Testing
- leukoglycemic index calculation
- Where
- Turkey (Türkiye)
- Volunteers
- 552 people
- Sponsor
- Kırıkkale University
Acute Coronary Syndrome
European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial
To show that the early administration of bivalirudin improves 30 day outcomes when compared to the current standard of care in participants with ST segment elevation acute coronary syndrome (STE-ACS), intended for a primary…
- Trial name
- EUROMAX (NCT01087723)
- Testing
- Bivalirudin, Heparin
- Where
- 145 sites in Austria, Czechia and 7 more
- Volunteers
- 2,198 people
- Sponsor
- The Medicines Company
Acute Coronary Syndrome
The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial
This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or urgent coronary revascularization (e.g.
- Trial name
- SOLID-TIMI 52 (NCT01000727)
- Testing
- Darapladib 160 mg, Standard Therapy
- Where
- 914 sites in United States, Argentina and 34 more
- Volunteers
- 13,026 people
- Sponsor
- GlaxoSmithKline
Acute Coronary Syndrome
The Effect on Blood Cells, Known as Platelets, Using Prasugrel vs Clopidogrel in Patients With the Heart Problem Acute Coronary Syndrome (ACS)
This is a multicenter, randomized, double-blind, cross-over study to compare the pharmacodynamic response in subjects with Acute Coronary Syndrome receiving a 10-mg maintenance dose (MD) of prasugrel compared with a 150-mg…
- Trial name
- NCT00385944
- Testing
- Prasugrel, Clopidogrel
- Where
- 2 sites in France
- Volunteers
- 56 people
- Sponsor
- Eli Lilly and Company
Acute Coronary Syndrome
MT1002 Phase II Study in ACS Patients With PCI
This is an open-label, sequential-dose escalation/de-escalation trial testing 3 dose levels of MT1002 in patients undergoing PCI due to ACS with NSTEMI.
- Trial name
- NCT04723186
- Testing
- MT1002 for Injection
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Chest Pain, Coronary Artery Disease
ARgentinean Risk Assessment Registry in ACS; the ARRA-RACS Study
The first aim of this trial is to assess the long-term prognostic value of Omega-3 index, which is a measure of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) relative to other fatty acids in the erythrocyte membrane…
- Conditions
- Chest Pain, Coronary Artery Disease, Unstable Angina Pectoris, Myocardial Infarction
- Trial name
- ARRA-RACS (NCT01377402)
- Where
- 10 sites in Argentina, Norway
- Volunteers
- 982 people
- Sponsor
- Helse Stavanger HF
Acute Coronary Syndrome, Depression
MBCT Delivered Via Group Videoconferencing for ACS Patients With Elevated Depression Symptoms
The objective of this study is to identify Acute Coronary Syndromes (ACS) patients' specific needs and preferences for depression treatment via in-person or virtual individual interviews to (a) guide MBCT adaptation; and identify…
- Conditions
- Acute Coronary Syndrome, Depression, Myocardial Infarction, Unstable Angina
- Trial name
- NCT03878160
- Testing
- Individual Interview
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Acute Coronary Syndrome
Ranolazine Cardioprotection in PCI
The investigators will test if upfront dosing of Ranolazine can reduce myocardial biomarker release (CK-MB, Troponin) post percutaneous coronary intervention (PCI).
- Trial name
- NCT01767987
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Harvey Hahn
ACS - Acute Coronary Syndrome
Positive Psychology for Acute Coronary Syndrome Patients
This is a randomized controlled pilot trial in approximately 50 acute coronary syndrome patients to determine if a 12 week, telephone-delivered, combined positive psychology-motivational interviewing intervention is feasible and…
- Trial name
- PEACE-IV (NCT03122184)
- Testing
- Positive Psychology + Motivational Interviewing, Motivational Interviewing Health Education
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Massachusetts General Hospital